General Updates

To To Date: August 25, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Clarification with respect to tentative timeline for utilization of net proceeds of Preferential Issue Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, This is in continuation of the Company's earlier intimations made in connection with the allotment of Convertible Warrants on a preferential basis, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Company hereby clarifies that the timeline for utilisation of the net proceeds / tenure of the Convertible Warrants is 18 months from the date of allotment, in accordance with the applicable provisions of Regulation 162 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and is subject to receipt of the requisite in-principle approval from the Stock Exchanges. Accordingly, the Company hereby confirms that there is no change in the objects of the Preferential Issue or the manner of utilisation of the proceeds. The present intimation is being made only to clarify the tentative timeline for utilisation of the net proceeds in view of the 18-month tenure of the Convertible Warrants. Kindly take the above information on record. Thanking You. For Bal Pharma Ltd Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681